Question 1

What is Cellenkos?

Accepted Answer

Cellenkos is a Entity.

Question 2

How often does Cellenkos appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 13 articles.

Question 3

When was Cellenkos first tracked by Ergen?

Accepted Answer

First tracked on Apr 27, 2026.

Question 4

When was Cellenkos last mentioned in news?

Accepted Answer

Last active on May 15, 2026.

Question 5

What is Cellenkos's current news sentiment?

Accepted Answer

Aggregate sentiment score: 72 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Cellenkos in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Cellenkos?

Accepted Answer

Cellenkos CK0801 FDA Phase 2 Clearance (Apr 27, 2026, 6 articles).

Question 8

How did the "Cellenkos CK0801 FDA Phase 2 Clearance" event impact Cellenkos?

Accepted Answer

Cellenkos, a clinical-stage biotechnology company, received FDA clearance to initiate a Phase 2 clinical trial for its CK0801 therapy, which is a significant positive development for the company.

Question 9

How did the "Cellenkos CK0802 IND Clearance" event impact Cellenkos?

Accepted Answer

Cellenkos received FDA clearance for its Investigational New Drug application for CK0802, allowing it to proceed with a Phase 1b/2a clinical trial for steroid-refractory GVHD. This is a major milestone for Cellenkos, validating its CRANE manufacturing platform and advancing its pipeline.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.